Beschreibung
Azithromycin and escitalopram each prolong the QT interval; co-administration meaningfully increases the risk of torsades de pointes.
Mechanismus
Both agents block cardiac hERG (IKr) channels; additive QTc prolongation may exceed the threshold for proarrhythmic risk.
Klinische Bedeutung
FDA QT safety communications exist for both agents independently; case reports link the combination to arrhythmic events.
Maßnahmen
Avoid concurrent use when possible; if unavoidable, obtain ECG, correct hypokalemia/hypomagnesemia, and limit duration of azithromycin course.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.